Πανελλήνιο Συνέδριο Καρκίνος Πνεύμονα Lung Cancer Network «From the Bench to the Bedside» - Results from #30

Πανελλήνιο Συνέδριο Καρκίνος Πνεύμονα Lung Cancer Network «From the Bench to the Bedside»

Επιλέξτε Μέρα

16-01-2020

Details: 17 βίντεο

17-01-2020

Details: 19 βίντεο

18-01-2020

Details: 24 βίντεο

31 A. Papaspiliou - Cases of special interest.

31 A. Papaspiliou - Cases of special interest.

32 E. Gӧker - Optimal 1st line treatment for mutation naive patients.

32 E. Gӧker - Optimal 1st line treatment for mutation naive...

33 Y. Eralp - Management of oligometastatic disease.

33 Y. Eralp - Management of oligometastatic disease.

34 Discussion

35 F. Hirsch - TMB as predictor of immuno-oncology therapy.

35 F. Hirsch - TMB as predictor of immuno-oncology therapy.

36 F. Detterbeck - Lung cancer surgery in the 21st century.

36 F. Detterbeck - Lung cancer surgery in the 21st century.

37 D. Rimm - Analytic approaches to understanding PD-L1 expression and mechanism of action.

37 D. Rimm - Analytic approaches to understanding PD-L1 expr...

38 N. Normanno - Liquid biopsies: facts and myths.

38 N. Normanno - Liquid biopsies: facts and myths.

39 F. Hirsch - Next Generation Sequencing: is there any clinical use?

39 F. Hirsch - Next Generation Sequencing: is there any clin...

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKIs.

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKI...

41 Discussion

42 L. Landi - Current treatment algorithms for EGFR-mutated patients.

42 L. Landi - Current treatment algorithms for EGFR-mutated...

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ patients.

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ pat...

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, ALK and ROS1.

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, AL...

45 Discussion

2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white